CANC Tema Oncology ETF
Holds 58 stocks in therapeutics and medical devices, 22% of its weight in S&P 500 companies
CANC holds 58 stocks, and 78% of its weight is outside the S&P 500.
Key facts
ETFIQ Off-Index Score
34.9242nd of 371
CANC shares 8 of its 58 holdings with the S&P 500. Only 4.4% of its weight overlaps the index.
How much of it is not the index it is sold as an alternative to?
That is the share of the 371 thematic ETFs with a holdings filing sitting at or below CANC. A position in this set, not a rating: it moves when the set moves, and it is not a figure to average against another desk's.
2nd of 5 therapeutics and medical devices ETFs by net assets 3rd of 5 therapeutics and medical devices ETFs by least weight in the S&P 500
Its ten largest equity positions
| Holding | Ticker | Weight | |
|---|---|---|---|
| REVOLUTION MEDICINES INC | RVMD | 5.57% | |
| COGENT BIOSCIENCES INC | COGT | 5.05% | |
| MERCK & CO INC | MRK | 4.69% | |
| ELI LILLY & CO | LLY | 4.50% | |
| NOVARTIS AG | NOVN | 3.60% | |
| BRISTOL-MYERS SQUIBB CO | BMY | 3.60% | |
| ABBVIE INC | ABBV | 3.52% | |
| JOHNSON & JOHNSON | JNJ | 3.27% | |
| BEONE MEDICINES LTD | ONC | 3.24% | |
| ROCHE HOLDING AG | RHHBY | 3.10% |
Period by period
| Window | Total return | S&P 500 | Gap to S&P 500 | Gap to Nasdaq-100 |
|---|---|---|---|---|
| 3 months | +10.8% | +3.3% | +7.5 pts | +11.6 pts |
| 6 months | +15.4% | +16.0% | −0.6 pts | −5.3 pts |
| 1 year | +49.6% | +17.5% | +32.1 pts | +26.6 pts |
| 3 years | +75.3% | +77.9% | −2.5 pts | −19.8 pts |
| Since launch | −30.3% | +90.0% | −120.2 pts | −135.8 pts |
In plain words
The top ten holdings are 40% of the fund across 58 positions, as published by its issuer for Sep 11, 2026. Over the year to Sep 11, 2026 the fund returned +49.6% with distributions reinvested against +17.5% for the S&P 500, so a holder was ahead by 32.1 pts. It sits 50.4% below its all-time high of Oct 20, 2021.
| Theme (ETFIQ, editorial) | Therapeutics and medical devices |
|---|---|
| Launched | Sep 30, 2021 |
| Already in the S&P 500, by weight (ETFIQ) | 22.2% |
| Active share vs the S&P 500 (ETFIQ) | 95.6% |
| Already in the Nasdaq-100, by weight (ETFIQ) | 2.3% |
| Active share vs the Nasdaq-100 (ETFIQ) | 98.5% |
| Top ten holdings weight | 40.1% |
| Holdings | 58 |
| Holdings published for (the issuer’s daily file) | Sep 11, 2026 |
| Top holdings | REVOLUTION MEDICINES INC 5.6%, COGENT BIOSCIENCES INC 5.0%, MERCK & CO INC 4.7%, ELI LILLY & CO 4.5%, NOVARTIS AG 3.6%, BRISTOL-MYERS SQUIBB CO 3.6%, ABBVIE INC 3.5%, JOHNSON & JOHNSON 3.3%, BEONE MEDICINES LTD 3.2%, ROCHE HOLDING AG 3.1% |
| Net assets (issuer page, as of Sep 11, 2026) | $203m |
| Below its all-time high (ETFIQ) | −50.4% |
| Expense ratio (485BPOS XBRL, Jun 29, 2026) | 0.75% |
| Fee for the part that differs from the S&P 500, active expense ratio (ETFIQ) | 0.78% |
Holdings from the file the issuer publishes daily; overlap and active share computed by ETFIQ against the IVV and QQQM books; returns from Tiingo end-of-day prices with distributions reinvested. How these figures are computed
Questions people ask
- How much of CANC is in S&P 500 companies?
- By its holdings published by its issuer for Sep 11, 2026, 22% of CANC by weight is stocks the S&P 500 already holds. Its active share against the index is 96%, so that share is the part doing something different.
- What does CANC hold?
- 58 positions as published by its issuer for Sep 11, 2026, with the top ten at 40% of the fund. The largest are REVOLUTION MEDICINES INC at 5.6%, COGENT BIOSCIENCES INC at 5.0%, MERCK & CO INC at 4.7%.
- Has CANC beaten the S&P 500?
- Over the year to Sep 11, 2026 CANC returned +49.6% with distributions reinvested, against +17.5% for the S&P 500, so it finished ahead of the index by 32.1 points.
- What does CANC cost?
- The prospectus expense ratio is 0.75% a year. Because 96% of the fund differs from the S&P 500, the fee on that differing part works out at 0.78%.
The words on this page
- Active share
- The part of the fund doing something the index is not, as a percentage. It is the part a fee is actually buying.
- Weight overlap
- The share of money two portfolios hold in the same securities at the same weight. Above 50%, holding both is close to holding one of them twice.
- Already in the index
- The fund’s weight in securities the S&P 500 holds at all. A fund can be made entirely of index names and still have high active share, because it holds them at very different weights.
- Top ten
- What the ten largest positions add up to. The higher it is, the more the fund is a bet on a few companies rather than a theme.
Every term used here, defined in full on the thematic ETFs vocabulary page.
Where these figures came from
ETFIQ links to the documents behind every figure. It is not affiliated with any issuer, and a link is not an endorsement.
Funds near this one
Put this on your own page
The difference bar for CANC, redrawn every trading night. Free to use with the credit link.
Where CANC is written about
Use this data, or open the live card
Open CANC live on ETFIQ, where the figures refresh with the data.
Cite this page. ETFIQ, CANC, thematic ETFs, data as of Sep 11, 2026. https://etfiq.com/funds/canc Free to use with attribution; the underlying files are at Open data.